Profile data is unavailable for this security.
About the company
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
- Revenue in USD (TTM)7.99m
- Net income in USD-40.58m
- Incorporated2014
- Employees41.00
- LocationCue Biopharma Inc40 Guest StreetBOSTON 02135United StatesUSA
- Phone+1 (617) 949-2680
- Fax+1 (302) 655-5049
- Websitehttps://www.cuebiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRX Pharmaceuticals Inc | 0.00 | -24.11m | 56.54m | 2.00 | -- | -- | -- | -- | -1.98 | -1.98 | 0.00 | -1.47 | 0.00 | -- | -- | -- | -423.80 | -210.73 | -- | -603.16 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 16.69 | -- | -- | -- |
| Adverum Biotechnologies Inc | 1.00m | -150.80m | 56.82m | 155.00 | -- | 2.14 | -- | 56.82 | -7.22 | -7.22 | 0.0479 | 1.27 | 0.0049 | -- | -- | 6,451.61 | -74.38 | -42.24 | -84.05 | -45.55 | -- | -- | -15,079.90 | -5,542.36 | -- | -- | 0.00 | -- | -72.22 | 31.95 | -7.22 | -- | -54.20 | -- |
| Vicapsys Life Sciences Inc | 0.00 | -1.35m | 57.30m | 2.00 | -- | -- | -- | -- | -0.0396 | -0.0396 | 0.00 | -0.0817 | 0.00 | -- | -- | 0.00 | -904.16 | -- | -- | -- | -- | -- | -- | -- | -- | -7.46 | -- | -- | -- | -- | -19.61 | -- | -- | -- |
| Maia Biotechnology Inc | 0.00 | -19.70m | 58.49m | 13.00 | -- | 11.55 | -- | -- | -0.8202 | -0.8202 | 0.00 | 0.167 | 0.00 | -- | -- | 0.00 | -191.49 | -208.29 | -371.24 | -373.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -17.61 | -- | -- | -- |
| Applied Therapeutics Inc | 266.00k | -43.51m | 58.63m | 35.00 | -- | 1.60 | -- | 220.40 | -0.3023 | -0.3023 | 0.0018 | 0.259 | 0.0026 | -- | -- | 7,600.00 | -41.81 | -142.89 | -81.89 | -278.61 | -- | -- | -16,357.52 | -4,856.82 | -- | -- | 0.00 | -- | -95.45 | -- | 11.81 | -- | -- | -- |
| Serina Therapeutics Inc | 65.00k | -939.00k | 58.77m | 12.00 | -- | 34.43 | -- | 904.12 | -0.0516 | -0.0516 | 0.0068 | 0.1713 | 0.0074 | -- | -- | 5,416.67 | -11.53 | -188.54 | -153.87 | -- | -- | -- | -1,560.00 | -7,513.03 | -- | -- | 0.00 | -- | -60.56 | -49.64 | 24.74 | -- | -49.05 | -- |
| INmune Bio Inc | 50.00k | -40.80m | 59.29m | 22.00 | -- | 1.72 | -- | 1,185.70 | -1.95 | -1.95 | 0.0024 | 1.29 | 0.0012 | -- | 0.0244 | 2,272.73 | -96.41 | -45.54 | -137.69 | -52.16 | -- | -- | -81,592.00 | -19,298.45 | -- | -96.12 | 0.00 | -- | -90.97 | -- | -40.24 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -35.50m | 59.42m | 24.00 | -- | 2.64 | -- | -- | -0.94 | -0.94 | 0.00 | 0.4921 | 0.00 | -- | -- | 0.00 | -61.18 | -57.93 | -85.84 | -68.38 | -- | -- | -- | -- | -- | -16.02 | 0.4588 | -- | -- | -- | 12.42 | -- | -- | -- |
| Cue Biopharma Inc | 7.99m | -40.58m | 59.98m | 41.00 | -- | 7.48 | -- | 7.51 | -0.6644 | -0.6644 | 0.1278 | 0.1064 | 0.2097 | -- | 11.42 | 194,902.40 | -106.51 | -60.20 | -190.46 | -73.56 | -- | -- | -507.87 | -683.99 | -- | -- | 0.339 | -- | 69.16 | 21.84 | 19.83 | -- | 7.32 | -- |
| Context Therapeutics Inc | 0.00 | -27.63m | 60.11m | 12.00 | -- | 0.6607 | -- | -- | -0.3469 | -0.3469 | 0.00 | 1.01 | 0.00 | -- | -- | 0.00 | -53.13 | -44.73 | -55.54 | -57.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.52 | -- | -- | -- |
| Senti Biosciences Inc | 0.00 | -54.79m | 60.51m | 34.00 | -- | 1.59 | -- | -- | -10.30 | -10.30 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -59.25 | -50.97 | -66.56 | -57.59 | -- | -- | -- | -2,565.78 | -- | -- | 0.00 | -- | -100.00 | -- | 36.71 | -- | -58.03 | -- |
| Adicet Bio Inc | 0.00 | -117.32m | 61.19m | 152.00 | -- | 0.379 | -- | -- | -1.29 | -1.29 | 0.00 | 1.95 | 0.00 | -- | -- | 0.00 | -48.44 | -36.24 | -52.09 | -39.41 | -- | -- | -- | -813.80 | -- | -- | 0.00 | -- | -- | -- | 17.90 | -- | 32.77 | -- |
| Medicinova Inc | 0.00 | -11.16m | 62.29m | 13.00 | -- | 1.25 | -- | -- | -0.2275 | -0.2275 | 0.00 | 1.02 | 0.00 | -- | -- | 0.00 | -19.35 | -15.56 | -20.16 | -16.17 | -- | -- | -- | -1,144.98 | -- | -- | 0.00 | -- | -100.00 | -- | -28.91 | -- | -39.68 | -- |
| CervoMed Inc | 9.31m | -18.67m | 62.75m | 15.00 | -- | 1.81 | -- | 6.74 | -2.14 | -2.14 | 1.07 | 3.98 | 0.3997 | -- | 11.43 | 620,547.30 | -80.17 | -54.89 | -93.42 | -60.99 | -- | -- | -200.58 | -428.45 | -- | -- | 0.00 | -- | 36.29 | -- | -650.08 | -- | -- | -- |
| Jupiter Neurosciences Inc | 0.00 | -3.33m | 63.23m | 4.00 | -- | 20.63 | -- | -- | -0.104 | -0.104 | 0.00 | 0.0926 | -- | -- | -- | 0.00 | -- | -383.24 | -- | -- | -- | -- | -- | -902.90 | -- | -20.74 | 0.0456 | -- | -- | -- | 49.00 | -- | -- | -- |
Data as of Jul 11 2025. Currency figures normalised to Cue Biopharma Inc's reporting currency: US Dollar USD
17.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bleichroeder LPas of 31 Mar 2025 | 5.00m | 7.89% |
| The Vanguard Group, Inc.as of 31 Mar 2025 | 2.30m | 3.64% |
| Park City Capital LLCas of 05 Jun 2024 | 1.00m | 1.58% |
| Geode Capital Management LLCas of 31 Mar 2025 | 693.89k | 1.10% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 559.80k | 0.88% |
| Robertson Stephens Wealth Management LLC (Invt Mgmt)as of 31 Mar 2025 | 478.50k | 0.76% |
| Sigma Planning Corp.as of 31 Mar 2025 | 326.26k | 0.52% |
| Bank of America, NA (Private Banking)as of 31 Mar 2025 | 324.34k | 0.51% |
| Advisory Research, Inc.as of 31 Mar 2025 | 257.23k | 0.41% |
| 1919 Investment Counsel LLCas of 31 Mar 2025 | 196.56k | 0.31% |
More ▼
Data from 05 Jun 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
